Targeting thyroid cancer microenvironment: basic research and clinical applications.
Nucera, Carmelo. 2013. “Targeting Thyroid Cancer Microenvironment: Basic Research and Clinical Applications.”. Frontiers in Endocrinology 4: 167.
Search
Search results
49 results found
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.
Shaik, Shavali, Carmelo Nucera, Hiroyuki Inuzuka, Daming Gao, Maija Garnaas, Gregory Frechette, Lauren Harris, et al. 2012. “SCF(β-TRCP) Suppresses Angiogenesis and Thyroid Cancer Cell Migration by Promoting Ubiquitination and Destruction of VEGF Receptor 2.”. The Journal of Experimental Medicine 209 (7): 1289-307.
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).
Nucera, Carmelo, Melanie Goldfarb, Richard Hodin, and Sareh Parangi. 2009. “Role of B-Raf(V600E) in Differentiated Thyroid Cancer and Preclinical Validation of Compounds Against B-Raf(V600E).”. Biochimica et Biophysica Acta 1795 (2): 152-61.
Dr. Nucera awarded with the prestigious Van Meter Award at the American Thyroid Association (ATA)
Link to Article
Helen Nguyen
Contact Us
Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.
Iesato, Asumi, Stephanie Li, Giovanni Roti, Michele R Hacker, Andrew H Fischer, and Carmelo Nucera. 2021. “Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.”. The Journal of Clinical Endocrinology and Metabolism 106 (12): 3569-90.
Clonal Reconstruction of Thyroid Cancer: An Essential Strategy for Preventing Resistance to Ultra-Precision Therapy.
McGonagle, Elizabeth R, and Carmelo Nucera. 2019. “Clonal Reconstruction of Thyroid Cancer: An Essential Strategy for Preventing Resistance to Ultra-Precision Therapy.”. Frontiers in Endocrinology 10: 468.
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?
Nucera, Carmelo, Jack Lawler, Richard Hodin, and Sareh Parangi. 2010. “The BRAFV600E Mutation: What Is It Really Orchestrating in Thyroid Cancer?”. Oncotarget 1 (8): 751-56.